Irisin: Emerging Therapeutic Targets for Cognitive Impairment-Related Diseases
- PMID: 40660735
- PMCID: PMC12315660
- DOI: 10.1017/erm.2025.10014
Irisin: Emerging Therapeutic Targets for Cognitive Impairment-Related Diseases
Abstract
Introduction: Irisin is a glycosylated polypeptide hormone derived from muscles that plays a crucial role in learning and memory by promoting the growth of hippocampal neurons, thereby influencing cognitive function.
Objective: Despite increasing evidence, a comprehensive understanding of the exact role of irisin remains elusive, necessitating further research to unravel the complex mechanisms through which irisin influences cognitive function and to explore therapeutic approaches targeting irisin.
Method: A literature review was performed by searching PubMed for articles published between 2012 and 2024, using the keywords ‘fibronectin type III domain-containing 5 (FNDC5)’, ‘irisin’, ‘cognitive impairment’, ‘Alzheimer’s disease’, ‘Age-related cognitive dysfunction’ and ‘Diabetes-associated cognitive dysfunction’, combined with Boolean operators (AND/OR).
Results: This review highlighted the potential impact of irisin on cognitive function in the context of ageing, diabetes and Alzheimer’s disease. The anti-cognitive impairment effects of irisin are associated with the regulation of energy metabolism, insulin resistance, inflammation, oxidative stress, amyloid-beta deposition, synaptogenesis and plasticity. The signalling pathways through which irisin improves cognitive impairment are complex and highly regulated processes, involving multiple signalling pathways such as the adenosine monophosphate-activated protein kinase (AMPK) signalling pathway, mitogen-activated protein kinase (MAPK) signalling pathway, nuclear factor-κB (NF-κB) signalling pathway, ERK-STAT3 signalling pathway, cAMP/PKA/CREB signalling pathway and Nrf2/HO-1 signalling pathway.
Conclusion: This review delves into the positive effects of irisin on cognitive impairment, examines the signalling pathways related to fibronectin type III domain-containing 5 (FNDC5)/irisin and provides future perspectives for research on the anti-cognitive impairment effects of irisin.
Keywords: AD; DACD; FNDC5; cognitive impairment; irisin.
Conflict of interest statement
The authors have no relevant financial or non-financial interests to disclose.
Figures
Similar articles
-
Short-Term Memory Impairment.2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31424720 Free Books & Documents.
-
Irisin ameliorates cognitive impairment in a lipopolysaccharide-induced neuroinflammation mouse model by inhibiting the NLRP3 inflammasome pathway in microglia.Neuropharmacology. 2025 Nov 1;278:110572. doi: 10.1016/j.neuropharm.2025.110572. Epub 2025 Jun 23. Neuropharmacology. 2025. PMID: 40562230
-
Empagliflozin and memantine combination ameliorates cognitive impairment in scopolamine + heavy metal mixture-induced Alzheimer's disease in rats: role of AMPK/mTOR, BDNF, BACE-1, neuroinflammation, and oxidative stress.Inflammopharmacology. 2025 Jun;33(6):3479-3498. doi: 10.1007/s10787-025-01755-5. Epub 2025 May 5. Inflammopharmacology. 2025. PMID: 40325262 Free PMC article.
-
Selegiline for Alzheimer's disease.Cochrane Database Syst Rev. 2003;(1):CD000442. doi: 10.1002/14651858.CD000442. Cochrane Database Syst Rev. 2003. PMID: 12535396
-
Potential role of FNDC5 in exercise-induced improvement of cognitive function.J Zhejiang Univ Sci B. 2025 May 23;26(6):557-572. doi: 10.1631/jzus.B2400016. J Zhejiang Univ Sci B. 2025. PMID: 40571660 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous